Our results indicated that anlotinib enhanced the intracellular accumulation of OXA in MDR cells (HCT116/L) and exhibited a strong effect on anti-angiogenesis, anti-metastasis, anti-proliferative and anti-multidrug resistance in CRC by blocking the EGFR, MET, and ABCB1 signaling pathways, which exhibited a robust pharmacological effect in the CRC Liver metastases xenograft model. This evidence concerns the gene ABCB1 and colorectal carcinoma.